Tempus has built the world’s largest library of clinical & molecular data and an operating system to make that data accessible and useful, starting with cancer.

Tempus can help physicians & healthcare providers make more informed treatment decisions, and provides opportunities for research collaborations. Learn more.

We deliver a comprehensive view of your patients through our tissue and liquid tests, DNA and RNA sequencing, somatic and germline tests, tumor-normal matched profiling, and MRD and monitoring test options.

Tempus Unlimited exists to provide a continuum of community based services that support the efforts of children and adults with disabilities to live as independently as possible in the least restrictive environment.

Find the latest Tempus AI, Inc. (TEM) stock quote, history, news and other vital information to help you with your stock trading and investing.

Tempus uses data and artificial intelligence (AI) to create precision medicine services, including diagnostics, [5] for oncology, cardiology, radiology, and depression. The company went public on the Nasdaq on June 14, 2024, under the ticker symbol "TEM."

Jan 13, 2025 · CHICAGO -- (BUSINESS WIRE)--Jan. 13, 2025-- Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced select, preliminary, unaudited results for the fourth quarter and full year ended December 31, 2024.

Jan 31, 2025 · Get a real-time Tempus AI, Inc. (TEM) stock price quote with breaking news, financials, statistics, charts and more.

Tempus One, which initially launched in 2023, provides both physicians and researchers AI-enabled services that leverage generative AI to propel privacy-enabled, data-driven decision...

Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence, including generative AI, in healthcare to create Intelligent Diagnostics.